Effects of GLP‐1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52‐Week Clinical Study

Compared with the placebo, GLP-1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP-1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.